Drug Discovery World

APRIL 8, 2024

Class B GPCRs are recognised as important targets for new medicines, particularly in chronic endocrine and metabolic diseases. grant supports drug discovery in metabolic diseases appeared first on Drug Discovery World (DDW). ConfoChimer technology enables universal ConfoBodies to be used across the GPCR superfamily.

Disease 130

Disease Small Molecule Drugs Treatment 130

Drug Discovery World

MAY 23, 2023

UK researchers at the Francis Crick Institute, Imperial College London and AstraZeneca will advance the discovery of new ‘molecular glues’ to treat a range of different diseases, thanks to a £11.2 Challenges arise when we can’t find a small molecule with the ability to interact with certain proteins, those we call ‘undruggable’.

Disease 130

Disease Small Molecule Laboratories Engineering 130

Drug Discovery World

MAY 24, 2023

million to develop the next generation of small molecule drugs against disease areas of high clinical need. The aim is to develop therapies with fewer side effects to treat diseases with a high clinical need. investment to target cancer and neurological diseases appeared first on Drug Discovery World (DDW).

Small Molecule 130

Small Molecule Disease Therapies Treatment 130

Drug Discovery World

DECEMBER 7, 2023

Inipharm has initiated Phase I dosing of its lead candidate, INI-822, which is a small-molecule inhibitor for HSD17B13, a gene implicated in nonalcoholic steatohepatitis (NASH). Loss-of-function variants of HSD17B13 are known to be associated with reduced incidence risk and severity of multiple liver diseases.

Disease 147

Disease Small Molecule Drugs Treatment 147

Drug Discovery World

OCTOBER 4, 2022

William Erhardt , President, Head of Development & Operations of biotech Oligomerix, tells Lu Rahman about the company’s differentiated approach to developing disease-modifying therapeutics for neurodegenerative diseases. . With its recent award of $3.35 With its recent award of $3.35 Overcoming sector challenges .

Disease 130

Disease Small Molecule Compound Screening Clinical Development 130

Drug Discovery World

MARCH 15, 2024

Biotechnology company Allyx Therapeutics has reported positive Phase Ib clinical data for its lead compound, ALX-001, a first-in-class, synapse-targeted, disease-modifying oral therapy in development for neurodegenerative diseases. The findings were presented at the AD/PD 2024 Conference in Lisbon.

Disease 130

Disease Trials Small Molecule Pharmacokinetics 130

Drug Discovery World

MAY 26, 2023

AM1476, a highly selective small molecule, delivered as an orally administered tablet, was found to be safe and well-tolerated at all relevant doses in a trial of approximately 100 healthy subjects. There are currently no treatments on the market that effectively reverse scarring.

Treatment 130

Treatment Small Molecule Trials Disease 130

Collaborative Drug

AUGUST 29, 2023

a new Italian incubator dedicated to the discovery and development of small molecule-based treatments for neurodegenerative diseases, announced today that it has adopted Collaborative Drug Discovery’s CDD Vault as its platform of choice for managing drug discovery data.

Small Molecule 82

Small Molecule Treatment Disease Research 82

Drug Discovery World

AUGUST 28, 2024

JT: We are developing novel small molecule, disease-modifying, allosteric regulators to treat serious diseases such as Parkinson’s disease and other dementias. Gain’s lead drug candidate GT-02287 is a best-in-class small molecule for the treatment of GBA-Parkinson’s disease and other neurodegenerative diseases.

Research 162

Research Small Molecule Disease Therapies 162

Drug Discovery World

NOVEMBER 11, 2022

BioSenic’s arsenic trioxide (ATO) autoimmune disease platform has completed a successful Phase IIb trial in chronic Graft vs Host Disease (cGVHD) and is preparing to move to a Phase III trial. . The properties of ATO as a small molecule are now well established,” said Prof François Rieger, President and CEO of BioSenic. .

Disease 130

Disease Small Molecule Medical Schools Trials 130

Drug Discovery World

JULY 27, 2022

Biotechnology company Recursion has been granted an Orphan Drug Designation for its potential treatment of the rare disease familial adenomatous polyposis (FAP). . As it stands there are no approved therapies for the disease. . Now, the European Commission has granted REC-4881 Orphan Drug Designation. . ” . .

Disease 130

Disease Small Molecule Clinical Trials Therapies 130

Drug Discovery World

SEPTEMBER 4, 2024

EVO756 is a highly selective small molecule antagonist of mas-related G-protein coupled receptor X2 (MRGPRX2) and could offer the potential for once-daily oral administration without the side effects observed with other therapies.

Clinical Trials 130

Clinical Trials Trials Small Molecule Clinical Development 130

Drug Discovery World

NOVEMBER 8, 2023

Over 19 million 1 hearts succumb to cardiovascular disease yearly, while around 10 million 2 lives are claimed by cancer every year. This advancement can refine clinical trials by improving participant selection based on molecular profiles, facilitating personalised treatments, and offering real-time tumour monitoring.

Clinical Trials 182

Clinical Trials Trials Disease Medical Schools 182

Drug Discovery World

JUNE 26, 2024

Spinogenix has initiated a Phase II trial to evaluate SPG302 for the treatment of adult participants with mild-to-moderate Alzheimer’s disease (AD), following approval for the trail in Australia. SPG302 is a once-a-day pill being developed as a regenerative treatment for neurodegenerative and neuropsychiatric diseases.

Small Molecule 189

Small Molecule Pharmacokinetics Drugs Clinical Trials 189

The Pharma Data

NOVEMBER 17, 2020

Lead Pharma has entered into a collaboration and license agreement with Roche , hoping to lead the way in the development of oral small molecules for immune-mediated diseases like rheumatoid arthritis, psoriasis and inflammatory bowel diseases. . Our ambition is to develop life-changing treatments for patients.

Small Molecule 52

Small Molecule Disease Immune Response Licensing 52

Drug Discovery World

FEBRUARY 8, 2023

EA-2353 takes a novel, small-molecule approach and selectively activates endogenous retinal stem and progenitor cells, which differentiate into photoreceptors and can potentially preserve or restore visual function. The drug was granted orphan drug designation by the FDA in May 2021.

FDA 130

FDA Treatment Small Molecule Disease 130

Drug Discovery World

DECEMBER 12, 2023

Exonate, an mRNA therapy company focused on treatments for diabetic complications, has announced that its lead ophthalmology asset, EXN407, has achieved its prespecified endpoints in a Phase Ib/IIa study. During the trial, EXN407 met all safety and pharmacokinetic parameters and displayed encouraging signals of biological activity.

Small Molecule 130

Small Molecule Trials Pharmacokinetics Treatment 130

Drug Discovery World

NOVEMBER 9, 2022

Poolbeg Pharma and partner OneThree Biotech have discovered novel drug targets for the treatment of respiratory syncytial virus (RSV) using an artificial intelligence (AI) programme. . The next stage will involve the identification of small molecule inhibitors to treat RSV infections.

Disease 130

Disease Small Molecule Virus Trials 130

Drug Discovery World

SEPTEMBER 5, 2024

Biotechnology company SeaBeLife has secured orphan drug designation (ODD) from the European Medicines Agency (EMA) for its drug candidate SBL01 in the treatment of acute liver failure (ALF). The committee considered that this constitutes a clinically relevant advantage.”

Small Molecule 147

Small Molecule Drugs Production Regulations 147

Drug Discovery World

JANUARY 11, 2024

Verge Genomics has initiated a Phase Ib proof-of-concept study for the treatment of sporadic and familial forms of amyotrophic lateral sclerosis (ALS) with VRG50635. ALS is a progressive neurodegenerative disease that affects motor neuron cells in the brain and spinal cord causing progressive paralysis of voluntary muscles.

Drug Trials 246

Drug Trials Trials Small Molecule Clinical Trials 246

Drug Discovery World

MAY 30, 2024

A new research paper has validated the mechanism of action of the Atrogi’s first-in-class, small molecule, ATR-127, in combating obesity and metabolic complications. We are now advancing our next generation small molecules for the treatment of obesity to IND preparatory studies in H1 next year and expect to enter the clinic in 2026.”

Small Molecule 147

Small Molecule Treatment International Production 147

The Pharma Data

JULY 28, 2021

Novel small molecule drug candidates will target GPR75 to potentially address obesity and related co-morbidities. AstraZeneca has entered into a collaboration with Regeneron to research, develop and commercialise small molecule compounds directed against the GPR75 target with the potential to treat obesity and related co-morbidities.

Small Molecule 52

Small Molecule Research Science Disease 52

Dark Matter Blog

AUGUST 27, 2020

A few years ago, at Arrakis Therapeutics, we set out to conquer a strange new territory, drugging RNA structures with small molecules. The efficiency of exon 7 inclusion in the mature SMN2 mRNA varies significantly among patients and poor inclusion efficiency correlates with higher disease severity.

Small Molecule 52

Small Molecule RNA Clinical Trials Drugs 52

Drug Discovery World

MARCH 15, 2024

Following the recent AD/PD 2024 conference, which took place on 5-9 March in Lisbon, Portugal, there have been a number of key announcements regarding investigational therapies for neurological disorders, particularly Alzheimer’s disease and Parkinson’s disease.

Small Molecule 130

Small Molecule Clinical Trials Drugs Trials 130

Drug Hunter

AUGUST 15, 2023

LRRK2 has been a hotly pursued drug target for Parkinson’s Disease based on human genetics. On Sunday, it was disclosed that additional, likely on-target adverse findings were observed in a primate GLP study on long-term treatment with Merck’s second-generation LRRK2 inhibitors. I ( NCT04557800 ).

Small Molecule 229

Small Molecule Trials Treatment Disease 229

Drug Discovery World

JULY 19, 2024

LT-HSCs are vital for bone marrow transplants as they can replenish the blood cells after treatment for blood cancers. This means that we rely on non-human, animal models to test drugs that can have effects on blood cell production and in targeting blood diseases (such as leukaemias).

Small Molecule 130

Small Molecule Drugs Engineering Disease 130

Drug Discovery World

MARCH 12, 2024

Lastly, for treatment of substance use disorders, few pipeline drugs are currently undergoing clinical trials, yet those in trial only address the withdrawal symptoms but not the underlying reward circuitry and the cravings. RA: What opportunity is there for better treatments in pain and mental health conditions?

Small Molecule 147

Small Molecule Synthetic Chemistry Production Molecular Biology 147

Drug Target Review

JULY 13, 2023

Drug discovery is a complex and vital field that continually seeks to identify new therapeutic targets and develop effective treatments. Dewpoint’s breakthrough was the realisation that certain condensates are associated with human diseases. Klein notes the importance of Dewpoint’s disease-agnostic approach.

Disease 98

Disease Small Molecule Cell Biology Medical Schools 98

Olympian Clinical Research

MAY 6, 2024

The journey toward effective treatments has been long and evolving, with recent breakthroughs offering new hope to those living with this challenging condition. From Coal Tar to Biologics: A Historical Perspective The history of psoriasis treatment is as old as the condition itself, with records dating back to ancient times.

Treatment 52

Treatment Small Molecule Immune Response Clinical Research 52

Drug Discovery World

MARCH 12, 2024

Lia Sylvestri, Director Customer Experience & Engagement , TrakCel “In 2024, significant advancements in monoclonal antibodies (mAbs) research are anticipated with leading companies, such as Roche, Regeneron, and Eli Lilly, expected to drive breakthroughs in precision medicine, tailoring mAbs for diverse diseases.

Molecular Biology 204

Molecular Biology Small Molecule Therapies FDA Approval 204

DrugBank

JULY 24, 2024

This is a game-changer, especially in the fight against cancer and other complex diseases. These multifunctional small molecules are like tiny spies, hijacking the body’s natural protein degradation system to remove unwanted proteins. This can potentially correct the root causes of some diseases at the genetic level.

Small Molecule 84

Small Molecule Clinical Trials Drugs Therapies 84

Drug Discovery World

AUGUST 18, 2023

My chosen news stories this week all discuss pre-clinical research studies that could have a huge impact on our therapeutic approach to several hard-to-treat diseases, helping to overcome drug-resistance and make treatments more targeted in the future.

Small Molecule 130

Small Molecule Virus Drugs Clinical Research 130

Drug Target Review

JULY 4, 2023

These therapies have broadened treatment options for patients to expand beyond the more traditional small molecule drug alternatives. ADCs have the potential to redress the poor balance between safety and efficacy seen with traditional cancer treatment options. 3D rendering of Antibody Drug Conjugate Molecules.

Small Molecule 145

Small Molecule Drugs Clinical Pharmacology Trials 145

PPD

JUNE 27, 2024

AA is considered a dermatology autoimmune disease, wherein the body fails to recognize its own cells and leads to subsequent immune-mediated destruction of the hair follicle. Accelerate your alopecia areata treatments. Learn more The post Advancing New Treatments for Alopecia Areata appeared first on PPD.

Treatment 52

Treatment Clinical Trials Small Molecule Clinical Research 52

Drug Discovery World

FEBRUARY 19, 2024

This move indicates that, despite the financial downturn, there are still acquisitions and funding releases, particularly in the gene therapy space and for those developing promising small molecule or biologic products that are potentially transformative for patients and where a relatively short timeline to market is likely (e.g.

Drug Development 147

Drug Development Small Molecule Drugs Therapies 147

Drug Discovery World

FEBRUARY 12, 2024

Cameron Ross, SVP, Generative AI, Elsevier “AI has the potential to dramatically shorten one of the most costly areas of early drug development – small molecule discovery. We’re already seeing biotechs making breakthroughs with AI in this area, with more than 150 small molecule drugs discovered and 15 already in clinical trials.

Small Molecule 349

Small Molecule Regulations Clinical Trials Therapies 349

Drug Discovery World

JANUARY 13, 2023

The preclinical start-up is working towards the development of first-in-class small molecule inhibitors of transglutaminase 2 (TG2), one of the major crosslinking enzymes in the human body, which becomes more active during ageing, resulting in fibrotic diseases. .

Small Molecule 130

Small Molecule Treatment Disease Research 130